<DOC>
	<DOCNO>NCT02982694</DOCNO>
	<brief_summary>The primary objective study determine anti-tumor activity , measure overall response rate ( ORR ) atezolizumab combination bevacizumab patient chemotherapy resistant CRC positivity MSI-like molecular signature . This international , open-label single arm ( non-randomized ) , one-stage phase II trial .</brief_summary>
	<brief_title>Study With Atezolizumab Plus Bevacizumab Patients With Chemotherapy Resistant , MSI-like , Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Activated Protein C Resistance</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written informed consent must give accord ICH/GCP national/local regulation . Histological cytological proof metastatic CRC . Disease progression relapse least one line treatment advance CRC fluoropyrimidine contain chemotherapy single agent combination ( combination oxaliplatin , irinotecan , bevacizumab , cetuximab panitumumab allow ) . Written documentation positivity MSIlike gene signature determine Agendia test . Unresectable disease , least one measurable lesion accord RECIST 1.1 . Age ≥ 18 year . WHO performance status 01 . Ability capacity comply study followup procedure . Adequate hematologic endorgan function , define follow laboratory result obtain within 28 calendar day prior first study treatment : ANC &gt; 1.5 x 109/L ( without granulocyte colonystimulating factor support within 2 week prior Cycle 1 , Day 1 ) WBC count &gt; 2500/μL Platelet count &gt; 100,000/ μL ( without transfusion within 2 week prior Cycle 1 , Day 1 ) Hemoglobin &gt; 9.0 g/dL AST , ALT , alkaline phosphatase &lt; 2.5 x ULN , follow exception : Patients document liver metastasis : AST ALT &lt; 5 x ULN Patients document liver bone metastasis : alkaline phosphatase &lt; 5 x ULN Bilirubin &lt; 1.5 x ULN . Patients know Gilbert disease serum bilirubin level &lt; 3 x ULN may enrol . PT PTT &lt; 1.5 x ULN , unless stable dose warfarin Serum albumin &gt; 2.5 g/dL Creatinine clearance &gt; 30 mL/min ( CockcroftGault formula base 24hour urine collection ) Protein &lt; 2+ dipstick urinalysis ≤ 1.0 g 24hour urine collection . All patient ≥2+ protein dipstick urinalysis baseline must undergo 24hour urine collection protein . Women child bear potential ( WOCBP ) must negative serum pregnancy test registration . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 6 month last bevacizumab treatment ( woman men ) 5 month last atezolizumab treatment ( woman ) . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Female subject breast feed discontinue nurse trial registration 6 month last bevacizumab treatment 5 month last atezolizumab treatment . Any treatment investigational drug ( bevacizumab consider investigational drug CRC ) within 28 day prior Cycle 1 , Day 1 . Previous cytotoxic agent within 14 day plan treatment initiation . Active untreated CNS metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) Note : Patients treat asymptomatic CNS metastasis eligible , provide meet follow criterion : Evaluable measurable disease outside CNS No metastases midbrain , pons , medulla , cerebellum , within 10 mm optic apparatus ( optic nerve chiasm ) No history intracranial spinal cord haemorrhage No ongoing requirement dexamethasone therapy CNS disease ; anticonvulsant stable dose allow . No evidence significant vasogenic edema . No stereotactic radiation , wholebrain radiation neurosurgical resection within 4 week prior Cycle 1 , Day 1 . Radiographic demonstration interim stability ( i.e. , progression ) completion CNSdirected therapy screen radiographic study . Screening CNS radiographic study &gt; 4 week since completion radiotherapy surgical resection &gt; 2 week since discontinuation corticosteroid . Symptomatic lesion amenable palliative radiotherapy ( e.g. , bone metastasis metastases cause nerve impingement ) treat least 14 day prior Cycle 1 , Day 1 . Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure ( monthly frequently ) . Previous ( within last 5 year ) concurrent malignancy , exception treat expected curative outcome conebiopsied situ carcinoma cervix , basal cell carcinoma skin , localized prostate cancer ductal carcinoma situ breast . Life expectancy &lt; 12 week . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . Positive test human immunodeficiency virus ( HIV ) . Active hepatitis B ( define positive hepatitis B surface antigen [ HBsAg ] test prior randomization ) hepatitis C. Note : Patients past hepatitis B virus ( HBV ) infection resolve HBV infection ( define negative HBsAg test positive antibody hepatitis B core antigen [ antiHBc ] antibody test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RNA . Active tuberculosis . Severe infection within 4 week prior Cycle 1 , Day 1 , include limited hospitalization complication infection , bacteremia , severe pneumonia . Signs symptoms infection within 2 week prior Cycle 1 , Day 1 . Received therapeutic oral IV antibiotic within 2 week prior Cycle 1 , Day 1 . Note : Patients receive routine antibiotic prophylaxis ( e.g. , prevent chronic obstructive pulmonary disease exacerbation dental extraction ) eligible . Significant cardiovascular cerebrovascular disease , New York Heart Association cardiac disease ( Class II great ) , unstable angina , history stroke , transient ischemic attack , myocardial infarction cerebrovascular event within previous 6 month unstable arrhythmia within previous 3 month : Patients know coronary artery disease , arrhythmia , congestive heart failure meeting criterion must stable medical regimen optimize opinion treat physician , consultation cardiologist appropriate . Baseline evaluation leave ventricular ejection fraction consider patient , especially cardiac risk factor and/or history coronary artery disease . Patients know leave ventricular ejection fraction &lt; 50 % . Major surgical procedure within 28 day prior cycle 1 , day 1 ( surgical wound fully heal ) , plan procedure surgery study . Prior allogeneic stem cell solid organ transplant . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . Prior treatment CD137 agonist , anti−CTLA4 , anti−PD1 , anti−PDL1 therapeutic antibody immunerelated pathwaytargeting agent . Current recent ( within 10 calendar day prior Cycle 1 , Day 1 ) use dipyridamole , ticlopidine , clopidogrel , cilostazol . Prophylactic therapeutic use low molecular−weight heparin ( e.g. , enoxaparin ) , direct thrombin inhibitor , warfarin permit , provide , appropriate anticoagulation index stable . Patients stable dose ( therapeutic use ) least two week ( reach steady state level drug ) prior first study treatment . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) ( Antihypertensive therapy achieve parameter allowable ) . Prior history hypertensive crisis hypertensive encephalopathy . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Cycle 1 , Day 1 . Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component bevacizumab atezolizumab formulation . Evidence bleed diathesis clinically significant coagulopathy ( absence therapeutic anticoagulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MSI</keyword>
	<keyword>colorectal</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Atezolizumab</keyword>
</DOC>